| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/07/2001 | CN1283181A Substituted beta-alanines |
| 02/07/2001 | CN1283180A Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas |
| 02/07/2001 | CN1283121A HIV-ITAT or derwatives thereof for prophylatic and therapeutic vacceination |
| 02/07/2001 | CN1282738A Improved method for sgnthesizing 6,9-bis[(2-aminoethyl) amino] benz[g] isoquinoline-5, 10-diketone and its dimaleate |
| 02/07/2001 | CN1282730A Compounds with particular structure and anticancer activity and its preparing process |
| 02/07/2001 | CN1282611A Process for separating antineoplastic component from glossy ganoderma spore |
| 02/07/2001 | CN1282580A Release-controlling coating of antineoplastic leurocristine |
| 02/07/2001 | CN1282578A Release-controlling coating of antineoplastic lomustine |
| 02/07/2001 | CN1061559C Medicine for treating myoma of uterus |
| 02/06/2001 | US6184422 Cyclohexanediol derivatives |
| 02/06/2001 | US6184374 Targeted cytotoxic anthracycline analogs |
| 02/06/2001 | US6184365 Anthracycline derivatives having 4-amino-2,4,6-trideoxy-2 fluoro-α-L-talopyranosyl group |
| 02/06/2001 | US6184357 Antibody which binds a preferential polypeptide; for the diagnosis, prevention and treatment of prostate cancer and hyperplasia |
| 02/06/2001 | US6184256 Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| 02/06/2001 | US6184237 Substituted pyridine compounds and methods of use |
| 02/06/2001 | US6184224 Drug resistance and side effect reduction |
| 02/06/2001 | US6184223 Reverse-turn mimetics and methods relating thereto |
| 02/06/2001 | US6184215 Treatment of skin conditions with oxysterol activators of LXRα |
| 02/06/2001 | US6184214 Hydrolysis of 2-dichlorophosphoryloxy-acrylonitrile to form 2-hydroxyacrylamide-o-monophosphate; antiischemic agents for treating disorders due to the lack of atp |
| 02/06/2001 | US6184212 Antisense modulation of human mdm2 expression |
| 02/06/2001 | US6184211 Inhibition of DNA methyltransferase |
| 02/06/2001 | US6184202 Modulating apoptosis of a cell by administering an agent comprising a bh1 or bh2 domain capable of promoting or inhibiting formation of a complex of bcl-2:blc-2; bcl-xl:bcl-xl; bax:bax; and/or bcl-xl:bax |
| 02/06/2001 | US6184032 Identification of genes encoding cell surface antigens using CREF-Trans 6 cells |
| 02/06/2001 | US6183751 Unique associated Kaposi's Sarcoma virus sequences and uses thereof |
| 02/06/2001 | US6183744 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 02/06/2001 | US6183734 Inhibition of tumor cell growth by administration of B7-transfected cells |
| 02/06/2001 | US6183721 A radioactive cyclic octapeptides for radiotherapy of somatostatin receptor positive tumors; antitumor agents |
| 02/06/2001 | CA2213798C Method for stimulating an immune response |
| 02/06/2001 | CA2147807C Bicyclic-aromatic compounds; pharmaceutical and cosmetic compositions containing them and uses |
| 02/06/2001 | CA2106299C Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| 02/05/2001 | CA2314867A1 2,7-substituted octahydro-1h-pyrido¬1,2-a|pyrazine derivatives as ligands for serotonin receptors |
| 02/05/2001 | CA2309313A1 Stimulation of the immune response by human dendritic cell manipulation |
| 02/01/2001 | WO2001007656A1 Antisense modulation of shp-1 expression |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007604A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | WO2001007602A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | WO2001007595A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | WO2001007594A1 Antisense modulation of mekk1 expression |
| 02/01/2001 | WO2001007483A1 Prognosis and therapy of malignant diseases by antibodies which bind phosphorylated met protein |
| 02/01/2001 | WO2001007481A1 Antitumor antibodies, proteins, and uses thereof |
| 02/01/2001 | WO2001007480A2 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 02/01/2001 | WO2001007476A1 26 human prostate and prostate cancer associated proteins |
| 02/01/2001 | WO2001007472A1 Highly purified cytokine activating factor and methods of use |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007470A2 Human nervous system-associated proteins |
| 02/01/2001 | WO2001007469A2 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | WO2001007466A1 Kinase blocking polypeptides and uses thereof |
| 02/01/2001 | WO2001007462A1 11β-ARYL-17,17-SPIROTHIOLANE-SUBSTITUTED STEROIDS |
| 02/01/2001 | WO2001007461A1 Antisense modulation of mekk5 expression |
| 02/01/2001 | WO2001007459A1 29 human secreted proteins |
| 02/01/2001 | WO2001007454A1 Enzyme catalyzed therapeutic activation |
| 02/01/2001 | WO2001007436A2 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | WO2001007424A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 02/01/2001 | WO2001007418A2 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 02/01/2001 | WO2001007417A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 02/01/2001 | WO2001007411A1 Biarylurea derivatives |
| 02/01/2001 | WO2001007408A2 Novel method for preparing benzoperhydroisoindole compounds |
| 02/01/2001 | WO2001007405A2 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | WO2001007088A2 Methods for treating therapy-resistant tumors |
| 02/01/2001 | WO2001007087A2 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | WO2001007082A1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007060A1 Compositions containing muscle-derived active agents |
| 02/01/2001 | WO2001007058A2 Parenteral cisplatin emulsion |
| 02/01/2001 | WO2001007046A1 Prenyl-protein transferase inhibitors |
| 02/01/2001 | WO2001007042A1 Apicidin-derived cyclic tetrapeptides |
| 02/01/2001 | WO2001007040A1 Multidrug-resistant cancer overcoming agents and process for producing the same |
| 02/01/2001 | WO2001007036A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN |
| 02/01/2001 | WO2001007029A2 Substituted guanidines and the use thereof |
| 02/01/2001 | WO2001007020A2 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof |
| 02/01/2001 | WO2001006990A2 Use of etodolac to treat cancer |
| 02/01/2001 | WO2001006983A2 Fatty acids to minimize cancer therapy side effects |
| 02/01/2001 | WO2000063352A3 Human homologues of fused gene |
| 02/01/2001 | WO2000061585A3 1,3-dipolar cycloadditions to polypyrrolic macrocycles |
| 02/01/2001 | WO2000061175A3 Use of pegylated interferon alpha in melanoma therapy |
| 02/01/2001 | WO2000059518A3 Composition and method for inducing apoptosis in prostate cancer cells |
| 02/01/2001 | WO2000053742A3 Polynucleotides and proteins encoded thereby |
| 02/01/2001 | WO2000050022A3 Treatment regimen for hormone-sensitive cancers |
| 02/01/2001 | WO2000043781A3 Growth differentiation factor inhibitors and uses therefor |
| 02/01/2001 | WO2000042832A3 New compounds for the treatment of cancer |
| 02/01/2001 | WO2000038717A3 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 02/01/2001 | WO2000037107A3 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |
| 02/01/2001 | WO1999066951A8 Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 02/01/2001 | WO1999041376A9 Retinoblastoma protein complexes and retinoblastoma interacting proteins |
| 02/01/2001 | WO1997045137A8 Methods and compositions useful for inhibition of angiogenesis |
| 02/01/2001 | DE19935771A1 Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln New vitamin D derivatives with cyclic substructures in the side chains, to processes and intermediates for their preparation and to the use for the preparation of medicaments |
| 02/01/2001 | DE19935219A1 Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung Carboxamides, medicaments containing these compounds, their use and production |
| 02/01/2001 | DE10031839A1 Erythropoietinkonjugate Erythropoietinkonjugate |
| 02/01/2001 | DE10022687A1 Gene-transfer vector containing an enhancer-promoter, useful for prevention or treatment of tumors, is able to enter normal tissue to prevent metastasis |
| 02/01/2001 | CA2383690A1 29 human secreted proteins |
| 02/01/2001 | CA2382755A1 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | CA2380389A1 Biarylurea derivatives |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380270A1 26 human prostate and prostate cancer associated proteins |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380192A1 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | CA2380178A1 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | CA2379863A1 Kinase blocking polypeptides and uses thereof |
| 02/01/2001 | CA2379859A1 Novel method for preparing benzoperhydroisoindole compounds |